Pharming Group (NASDAQ:PHAR - Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $10.02, but opened at $10.60. Pharming Group shares last traded at $10.60, with a volume of 199 shares trading hands.
Wall Street Analyst Weigh In
PHAR has been the subject of several recent analyst reports. HC Wainwright reissued a "buy" rating and set a $37.00 price objective on shares of Pharming Group in a report on Thursday, March 20th. Oppenheimer increased their price target on shares of Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a research report on Friday, March 14th.
Check Out Our Latest Stock Analysis on Pharming Group
Pharming Group Trading Up 8.3%
The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The business's fifty day simple moving average is $8.95 and its 200 day simple moving average is $8.90. The stock has a market cap of $781.00 million, a price-to-earnings ratio of -44.15 and a beta of -0.08.
Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03. The business had revenue of $79.09 million during the quarter, compared to analyst estimates of $67.74 million. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. On average, research analysts predict that Pharming Group will post -0.2 EPS for the current year.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Stories
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
